Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.48) by 18.75 percent. This is a 83.19 percent increase over losses of $(3.39) per share from the same period last year.